April 7, 2021Qelbree, a new nonstimulant medication for ADHD, has received FDA approval for treatment of attention deficit hyperactivity disorder in patients 6 to 17 years of age.
Qelbree is the first nonstimulant ADHD medication to receive FDA approval for use in children in more than a decade. Intuniv was the last branded, non-scheduled ADHD medication to be approved by the FDA in 2009.
Supernus plans to launch Qelbree in the U.S. in the second quarter, during back-to-school season for many families.Formerly known as SPN-812, Qelbree is a serotonin norepinephrine modulating agent.
Read more on additudemag.com